Cullinan Therapeutics, Inc. CGEM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$49.66M+2.1% | -$50.71M-0.2% | -$50.61M+27.8% | -$70.06M-44.4% | -$48.5M-1.8% | ||
| $79K0.0% | $79K0.0% | $79K+2.6% | $77K+1.3% | $76K-1.3% | ||
| $7.62M+4.2% | $7.31M-22.8% | $9.47M-4.2% | $9.89M+5.5% | $9.37M-2.7% | ||
| $1.67M+290% | -$879K— | —— | —— | $1.72M+496% | ||
| $662K+179% | -$840K-5.3% | -$798K+77.3% | -$3.52M-102% | -$1.74M-207% | ||
| -$46.05M-20.8% | -$38.11M-3.3% | -$36.88M+36.0% | -$57.61M-33.5% | -$43.16M-17.8% | ||
| —— | $11K— | —— | —— | —— | ||
| $20.14M+2.7% | $19.6M+55.9% | $12.57M-84.0% | $78.53M-37.6% | $125.84M-25.1% | ||
| $32.41M+44.8% | $22.39M-66.8% | $67.39M+26.2% | $53.4M+45.1% | $36.81M— | ||
| —— | $0— | $0— | —— | —— | ||
| —— | $0— | $0— | —— | —— | ||
| $380K-46.9% | $715K— | $0-100% | $373K— | $0-100% | ||
| -$13.25M— | —— | $30.52M+896% | -$3.84M+39.6% | -$6.35M+66.7% | ||
| —— | —— | —— | -$2.97M— | $0— | ||
| -$4.31M-170% | $6.18M+12.7% | $5.49M+240% | $1.61M+131% | -$5.26M-176% | ||
| $662K+179% | -$840K-5.3% | -$798K+77.3% | -$3.52M-102% | -$1.74M-207% | ||
| $380K-46.9% | $715K— | $0-100% | $373K— | $0-100% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cullinan Therapeutics, Inc. generate?
- Cullinan Therapeutics, Inc. (CGEM) generated -$178.6M in operating cash flow over the trailing twelve months.
- What is Cullinan Therapeutics, Inc.'s free cash flow?
- After $11.0K of capital expenditures, Cullinan Therapeutics, Inc.'s free cash flow was -$145.2M over the trailing twelve months, down 19.4% year over year.
- Where does Cullinan Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.